- OncoGel- Clinical trials (e.g., esophageal cancer) showed local paclitaxel release but no significant impact on overall tumor response, leading to study termination in some cases.- OncoGel: Developed by MacroMed Inc. and Boston Scientific Corporation, with clinical trials conducted in the late 2000s to early 2010s. No current activity suggests discontinuation or shift in focus.